<DOC>
	<DOC>NCT01511172</DOC>
	<brief_summary>This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effect on glycemic control of NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with OHAs (oral hypoglycaemic agents).</brief_summary>
	<brief_title>Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients diagnosed with type 2 diabetes and treated with at least 50 % of maximum dose(s) of OHA(s) for at least three months Duration of type 2 diabetes diagnosis at least one year HbA1c 8.013.0%, both inclusive Body Mass Index (BMI) between 2540 kg/m^2, both inclusive. Current treatment with thiazolidinediones or insulin initiated within the last four months prior to trial Impaired liver function Impaired renal function Cardiac problems Uncontrolled treated/untreated hypertension Cancer or any clinically significant disease or disorder, except for conditions associated to the type 2 diabetes, which in the Investigator's opinion could interfere with the results of the trial Recurrent major hypoglycaemia as judged by the Investigator Known or suspected allergy to trial product or related products Use of any drug (except for OHAs), which in the Investigator's opinion could interfere with the glucose level Known or suspected abuse of alcohol or narcotics Any contraindications to metformin or glimepiride according to the local guidelines</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>